[HTML] plos.org

[HTML][HTML] Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer

JA Meyerhardt, M Ancukiewicz, TA Abrams, D Schrag… - PLoS …, 2012 - journals.plos.org
Background To determine the maximum tolerated dose (MTD) and safety, and explore
efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line …
被引用次数：45 相关文章

Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer

JA Meyerhardt, M Ancukiewicz, TA Abrams… - PloS …, 2012 - pubmed.ncbi.nlm.nih.gov
Background To determine the maximum tolerated dose (MTD) and safety, and explore
efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line …

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer.

JA Meyerhardt, M Ancukiewicz, TA Abrams… - PLoS …, 2012 - search.ebscohost.com
Background: To determine the maximum tolerated dose (MTD) and safety, and explore
efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line …
[PDF] psu.edu

[PDF][PDF] Phase I Study of Cetuximab

JA Meyerhardt, M Ancukiewicz, TA Abrams… - … Vandetanib (ZD6474) as, 2012 - Citeseer
Background: To determine the maximum tolerated dose (MTD) and safety, and explore
efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line …

Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

JA Meyerhardt, M Ancukiewicz, TA Abrams, D Schrag… - Plos one, 2012 - europepmc.org
Background To determine the maximum tolerated dose (MTD) and safety, and explore
efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line …

[引用][C] Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer

JA Meyerhardt, M Ancukiewicz, TA Abrams… - PLoS …, 2012 - ui.adsabs.harvard.edu
Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with
Previously Treated Metastastic Colorectal Cancer - NASA/ADS Now on home page ads icon ads …
[HTML] nih.gov

[HTML][HTML] Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer

JA Meyerhardt, M Ancukiewicz, TA Abrams, D Schrag… - PLoS ONE, 2012 - ncbi.nlm.nih.gov
Background To determine the maximum tolerated dose (MTD) and safety, and explore
efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line …
[PDF] semanticscholar.org

[PDF][PDF] Phase I Study of Cetuximab

JA Meyerhardt, M Ancukiewicz… - Irinotecan, and …, 2012 - pdfs.semanticscholar.org
Background: To determine the maximum tolerated dose (MTD) and safety, and explore
efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line …

Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer

JA Meyerhardt, M Ancukiewicz, TA Abrams, D Schrag… - PLoS ONE, 2012 - hero.epa.gov
BACKGROUND: To determine the maximum tolerated dose (MTD) and safety, and explore
efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line …

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer

JA Meyerhardt, M Ancukiewicz, TA Abrams, D Schrag… - PLoS ONE, 2012 - go.gale.com
Colorectal cancer is the fourth most common malignancy and second most frequent cause of
cancer-related death in the United States, with 141,210 new cases and 49,380 deaths …